OBJECTIVE: Prader --Willi syndrome (PWS) is a genetic neurodevelopmental disorder with several nutritional phases during childhood proceeding from poor feeding, through normal eating without and with obesity, to hyperphagia and life-threatening obesity, with variable ages of onset. We investigated whether differences in appetite hormones may explain the development of abnormal eating behaviour in young children with PWS. SUBJECTS: In this cross-sectional study, children with PWS (n ¼ 42) and controls (n ¼ 9) aged 7 months --5 years were recruited. Mothers were interviewed regarding eating behaviour, and body mass index (BMI) was calculated. Fasting plasma samples were assayed for insulin, leptin, glucose, peptide YY (PYY), ghrelin and pancreatic polypeptide (PP). RESULTS: There was no significant relationship between eating behaviour in PWS subjects and the levels of any hormones or insulin resistance, independent of age. Fasting plasma leptin levels were significantly higher (mean±s.d.: 22.6±12.5 vs 1.97 ± 0.79 ng ml À1 , P ¼ 0.005), and PP levels were significantly lower (22.6 ± 12.5 vs 69.8 ± 43.8 pmol l À1 , Po0.001) in the PWS group compared with the controls, and this was independent of age, BMI, insulin resistance or IGF-1 levels. However, there was no significant difference in plasma insulin, insulin resistance or ghrelin levels between groups, though PYY declined more rapidly with age but not BMI in PWS subjects. CONCLUSION: Even under the age of 5 years, PWS is associated with low levels of anorexigenic PP, as in older children and adults. Hyperghrelinaemia or hypoinsulinaemia was not seen in these young children with PWS. Change in these appetite hormones was not associated with the timing of the transition to the characteristic hyperphagic phase. However, abnormal and/or delayed development or sensitivity of the effector pathways of these appetitive hormones (for example, parasympathetic and central nervous system) may interact with low PP levels, and later hyperghrelinaemia or hypoinsulinaemia, to contribute to hyperphagia in PWS.
INTRODUCTION
Prader-Willi syndrome (PWS) is a genetic neurodevelopmental disorder from a contiguous gene syndrome involving maternally imprinted genes within a critical 121-kb chromosomal region at 15q11-q13. 1 --4 This results in a number of neuroendocrine abnormalities including hypogonadism, growth hormone deficiency, hyperphagia and morbid obesity.
PWS has several distinct nutritional phases during its natural history. 5, 6 In our UK study, examining young children with PWS after initial neonatal failure-to-thrive there was stability of body mass index (BMI) from 15 to 30 months, after which there was a progressive BMI rise predating the age when parents noted an increase in eating behaviour. 5 Some eating issues (eating code 3, Table 1 ) were present at a median of 43 months, and important eating issues (hyperphagia and foraging, eating codes 4 and 5) were present at 52 --55 months.
Similarly a USA study described three main phases of eating behaviour in PWS. 6 In utero there is growth restriction (phase 0). In phase 1 the infant is hypotonic and not obese, with sub-phase 1a characterised by difficulty feeding with or without failure-tothrive, and in sub-phase 1b the infant grows steadily along a growth curve and weight increases at a normal rate. Phase 2 is associated with weight gain: in sub-phase 2a weight gain without a significant change in appetite or caloric intake is seen, whereas in sub-phase 2b there is a concomitant increased interest in food. Phase 3 is characterised by more marked hyperphagia, typically accompanied by food seeking and lack of satiety. The switch to hyperphagia (start of phase 2b) occurred at a median age of 54 months (quartiles 36 and 63 months), while phase 3 began at a median of 8 years (quartiles 5 and 13 years).
The marked propensity to excessive eating causes significant morbidity and mortality in PWS. 3, 7 Obesity can only be prevented by strict control over access to food, and, so far, various medications and surgical procedures to control eating behaviour have proved ineffective or with significant side effects. 3, 8 The hyperphagia has a variable age of onset, and, so far, no identified precipitating factor or underlying mechanism has accounted for this phenotypic change. If particular associations were identified this in turn might inform interventions to prevent obesity.
It is proposed that the normal feedback mechanisms that result in metabolic and psychological changes associated with food intake are impaired in PWS. 2, 9, 10 Evidence for this comes from both studies of eating behaviour and brain activation studies.
have revealed cortical and hypothalamic abnormalities in PWS. 2, 16, 17 Many peripheral circulating hormones regulate appetite and eating behaviour, including anorexigenic fat-derived leptin, intestinal cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) 3--36, and from the pancreas insulin and pancreatic polypeptide (PP), and stomach-derived orexigenic ghrelin. 18 --20 Many studies have shown abnormalities in the circulating levels of these hormones in PWS that might contribute to their hyperphagia, including fasting and/or post-prandial hypoinsulinaemia (related to preserved insulin sensitivity), PP deficiency and hyperghrelinaemia, while CCK, GLP-1, PYY and leptin levels do not appear to be deficient in PWS. 10,11,20 --48 However, appetitive hormonal abnormalities may depend on the age of the PWS patients studied, raising the possibility that changes in these hormones may explain the changing natural history of the eating behaviour. We hypothesised that changes in the levels of these hormones might contribute to the emergence of the hyperphagic phenotype over a variety of ages in young PWS children. This factor has not been reported in studies of younger children where simple age cutoffs have been used.
We have already reported on the changing proportions of the genetic subtypes; pregnancy, birth and neonatal problems, and BMI trajectories and eating behaviour in a cohort of young children with PWS in the UK aged 0 --5 years. 5, 49, 50 In this study, we report measurements of the plasma appetitive hormones (ghrelin, insulin, leptin, PYY and PP) in this cohort to compare with their eating behaviour.
METHODS Participants
Children with genetically confirmed PWS aged below 5 years were recruited through the UK PWS Association (n ¼ 42). The number with each genotype was: chr 15q11-13 deletion (n ¼ 20), uniparental disomy (n ¼ 19), imprinting centre defect (n ¼ 2), uniparental disomy or imprinting defect (n ¼ 1). A total of 16 (38%) subjects with PWS were receiving growth hormone (GH) therapy at the time of study, and had been receiving GH for 17.9 ± 16.2 months (range 1.0 --53.7). Control children, matched for age, were recruited from patients having routine blood samples collected before surgery (n ¼ 9) on eye (squint correction) or ear (cochlear implant) at Addenbrookes Hospital. Ethical approval was obtained from the Cambridge REC and mothers gave informed consent.
Procedures
Using a structured interview, information was obtained from mothers regarding eating behaviour including controls imposed and food interests. An eating code was assigned to each PWS child, based on the answers (Table 1) . 5 Fasting blood samples were collected for plasma or serum to be assayed for insulin and leptin (lithium heparin plasma), PYY, ghrelin and PP (lithium heparin plasma-containing Aprotonin (Trasylol) 200 KIU ml À1 whole blood), glucose (fluoride oxalate plasma) and IGF-1 (serum). All bloods samples were collected in the morning after an overnight fast, except for small babies still having regular feeds who were fasted for around 6 h.
Hormone assays
Ghrelin (total, both octanoyl and des-octanoyl ghrelin), PYY and PP were measured using in-house radioimmunoassay, 38, 51 leptin (R&D Systems Europe, Abingdon, UK) and insulin (Perkin Elmer Life Sciences, Turku, Finland) by dissociation-enhanced lanthanide fluorescent immunoassay, IGF-1 by automated immunoassay (Siemens Immulite 2000, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) and glucose by hexokinase method. Intra-assay CVs were o10%. All assays were performed in a single run. Homeostasis model insulin resistance index (HOMA-IR) was calculated using fasting insulin and glucose concentrations. 52 
Statistical analysis
For comparison between groups Mann --Whitney rank sum test was used. Pearson product moment correlation coefficients (r) assessed the relationship between variables. Examination of the effect of PWS on hormones (dependent variable), adjusting for differences in age, BMI, HOMA-IR and other hormones (independent variable), was performed using multiple linear regression analysis to calculate the PWS regression coefficient (b). Log 10 transformation was used to normalise data that was not normally distributed in regression analysis. The interaction coefficient (PWS x independent variable) was also included initially in the model to look for any significant difference in the slope of the regression lines between groups. If non-significant the interaction coefficient was excluded from the subsequent analysis. Similar analysis assessed the effect of GH usage on hormones in PWS.
Results are presented as mean ± s.d. with significance Po0.05 using SigmaStat 2.03 (SPSS Inc.).
RESULTS

Demographics and anthropometrics
Subject details are given in Table 2 . PWS subjects were of similar average age, weight, BMI and BMI SDS to controls but had significantly lower weight SDS and height SDS scores. BMI SDS increased with age in PWS subjects (r ¼ þ 0.52, Po0.001) (Figure 1a ).
Plasma hormones and metabolites
Comparison of plasma hormone and HOMA-IR between groups is given in Table 2 , while their correlations with age, BMI and HOMA-IR are given in Table 3 .
In PWS subjects, fasting insulin and HOMA-IR had significant positive correlations with age (Po0.001 and 0.01), BMI and BMI Table 1 . Eating codes in PWS subjects Vignettes were composed using the information provided by parents in response to questions about their child's present eating behaviour in comparison with siblings and/or peers. This included information on the degree of interest in food, perceived hunger at meals, amount of food eaten, controls required, demands for food at and between meals, whether the child ever refused or left food, attitude to food routine, responses to food refusal, temper tantrums related to food issues, food-focused conversation, food-focused play, taking unauthorised food, the necessity to keep food out of sight, eating inappropriate or non-food items and active foraging. With reference to these descriptions each participant's eating behaviour was coded (see below). These codings were established independently by two researchers, with an inter-rater reliability Kappa ¼ 0.72 (P ¼ 0.0001). A total of 36 were complete agreements, and disagreements were never more than one scale point apart. All ratings were undertaken independent of knowledge of the child's weight.
Eating codes 1 ¼ No obvious eating issues. 2 ¼ Minor eating issues.
For example, always eating what was provided or occasionally taking unauthorised/inappropriate food, which could be regarded as within normal range or age-appropriate; in these cases mothers did not usually consider there to be any problem. 3 ¼ Some noticeable eating issues, above and beyond the above. 4 ¼ Important eating issues but no foraging.
3 and 4 were coded in relation to increasing numbers of issues or unusual behaviours recorded, usually accompanied by increasing maternal concern. 5 ¼ Important eating issues and foraging.
Fully developed syndrome with foraging (there are limitations on this definition in that children must be mobile, crawling at least).
SDS (both Po0.01) ( Table 3) . Leptin also had a significant positive correlation with BMI, BMI SDS and HOMA-IR (Po0.001, o0.001, 0.002, respectively) ( Table 3) . By contrast, fasting PYY in PWS subjects was negatively correlated with age, BMI and BMI SDS (Po0.001, 0.030, 0.016, respectively) (Table 3, Figure 1b ). Ghrelin levels were negatively correlated with age (P ¼ 0.048) ( Table 3 , Table 1 ). Figure 1d ).
In controls, leptin was positively correlated with HOMA-IR (P ¼ 0.019) and ghrelin was negatively correlated with age (P ¼ 0.029) ( Table 3) .
There was neither a significant difference in the nature of the correlation (interaction coefficient) of insulin, HOMA-IR, IGF-1, PP, leptin or ghrelin with age, BMI or BMI SDS between PWS and controls (interaction coefficient) nor of PP, leptin or ghrelin with insulin or HOMA-IR between groups (Figures 1c  and d, Table 3 ). There was a significant difference in the effect of age on PYY between groups, with PYY declining more significantly with age in the PWS compared with the controls (interaction coefficient b for log 10 PYY À0.516 ± 0.253, P ¼ 0.047) (Figure 1b) . This may be related to the increasing BMI in PWS (Figure 1a) , as there was no difference in the interaction coefficient when comparing the correlation of PYY with BMI or BMI SDS between groups (P ¼ 0.46 --0.63).
There was no significant difference in plasma IGF-1, insulin, HOMA-IR between groups (P ¼ 0.42 --0.75, Table 2 ) or when correcting for age, BMI and BMI SDS (P ¼ 0.55 --0.96). There was also no significant difference in average plasma ghrelin levels between groups (P ¼ 0.65 --0.73, Table 2 ) or when correcting for age (Figure 1c ), or in ghrelin or PYY correcting for BMI, BMI SDS or HOMA-IR (P ¼ 0.48 --0.96).
Fasting PP levels (22.6±12.5 vs 69.8±43.8 pmol l À1 , Po0.001) were significantly lower in the PWS group compared with the controls (Table 2) . This difference in PP between groups also remained significant when correcting for age (Figure 1b) , BMI, BMI SDS, insulin, HOMA-IR, insulin and age, HOMA-IR and age, IGF-1 or leptin (all Po0.001).
Fasting plasma leptin levels were significantly higher in the PWS group compared with the controls (22.6 ± 12.5 vs 1.97 ± 0.79 ng ml À1 , P ¼ 0.005) ( Table 2 ). This difference in plasma leptin between groups remained significant when adjusting for HOMA-IR, age and HOMA-IR (P ¼ 0.043 and 0.040), and IGF-1 (P ¼ 0.038), and had a tendency to remain significant when correcting for age, BMI or BMI SDS (P ¼ 0.051 --0.059).
GH treatment in PWS PWS subjects receiving GH were significantly older than those not receiving GH (44.8 ± 15.9 vs 25.1 ± 16.4 months, Po0.001), but there was no significant effect of GH usage on BMI or BMI SDS correcting for age (P ¼ 0.78 --0.87).
GH treatment increased the positive relationship of age with IGF-1 levels (interaction coefficient b 39.3 ± 13.2, P ¼ 0.005). However, there was no significant effect of GH treatment on the relationship (interaction coefficient) between age and plasma ghrelin, insulin, HOMA-IR, PYY, PP or leptin (P ¼ 0.37 --0.96). Correcting for age, there was no significant effect of GH treatment on plasma ghrelin, insulin, HOMA-IR, PP or leptin in PWS subjects (P ¼ 0.12 --0.83). There was a tendency for PYY levels in PWS subjects receiving GH to be 78.3% (SE 69.2, 88.7, P ¼ 0.058) lower than in those not receiving GH, correcting for age.
Eating code
In PWS subjects, eating code increased significantly with increasing age, BMI, BMI SDS, fasting insulin and HOMA-IR, and was negatively correlated with fasting PYY (Table 4, Figure 1b) . However, none of these correlations with plasma hormones remained significant when adjusting for age in multiple regression analysis (P ¼ 0.29 --0.43) (Table 4, Figure 1b) . Meanwhile, eating code was not correlated with fasting PP, leptin or ghrelin levels ( Table 4 , Figures 1c and d) .
There was no significant difference in fasting PP levels between PWS subjects with eating code 4 --5 (23.4 ± 13.9 pmol l À1 , range 14.2 --77.8), compared with those with eating code 1 --3 (20.7±8.1 pmol l À1 , range 10.0 --35.0, P ¼ 0.83) or when adjusting for age (P ¼ 0.94) (Figure 1d ). Furthermore, a lower PP level was seen in both PWS subjects with eating code 1 --3 compared with the controls (Po0.001), and PWS subjects with eating code 4 --5 compared with the controls (P ¼ 0.001).
While fasting ghrelin levels were lower in those PWS subjects with eating code 4 --5 (920 ± 515 pmol l À1 , range 201 --2179), compared with those with eating code 1 --3 (1239±460 pmol l À1 , range 485 --2837, P ¼ 0.029), this difference was not significant when adjusting for age (P ¼ 0.31) (Figure 1c , range 42.8 --215.7, P ¼ 0.001), but this difference did not quite reach significance when adjusting for age (P ¼ 0.08) (Figure 1c ).
DISCUSSION
We investigated whether any appetitive hormones could be a trigger for the switch in PWS phenotype, from a child with reduced or normal interest in feeding to one with an abnormal interest in food and propensity to over-eating and obesity. We could not find evidence for changes in fasting levels of ghrelin, PP, PYY, leptin or insulin to be related to the changing PWS eating phenotype in this cross-sectional study.
We found that in PWS children under 5 years, as expected, increase in fasting insulin and insulin resistance were seen with increasing age and BMI, and for leptin also with increasing insulin resistance. By contrast, fasting PYY was negatively correlated with age and BMI, while ghrelin was negatively correlated with age in PWS but not related to BMI. Fasting PP did not appear influenced by age, BMI or insulin resistance.
There was no significant relationship between eating behaviour and the development of hyperphagia in PWS subjects and the levels of any hormones independent of age. Compared with the controls, fasting plasma leptin levels were significantly higher and PP levels significantly lower in PWS, and this was independent of age, BMI, insulin resistance or IGF-1 levels. By contrast, there was no significant difference in plasma insulin, insulin resistance, ghrelin or PYY levels between PWS and controls, although PYY levels declined more rapidly with age but not BMI in PWS.
This suggests that changes in the absolute levels of these appetitive hormones over time are unlikely to contribute to the development of hyperphagia in PWS children. There remains the possibility that changes in some hitherto unknown circulating substance related to the regulation of eating behaviour does trigger the shift in the PWS eating phenotype. Alternatively, the change may be at the level of central feeding pathways of the hypothalamus, reward systems and/or autonomic nervous system (and therefore not identifiable peripherally). 19, 20 Such a target for circulating hormones might be one that (i) develops normally and around the same age of 4 --5 years as controls, (ii) develops normally but later in age than controls, (iii) is abnormal in PWS but not delayed or (iv) is both abnormal and delayed in development.
Thus, it is possible that while the hormonal abnormalities in PWS, such as hyperghrelinaemia, PP deficiency and hypoinsulinaemia, contribute to hyperphagia, their changes are not responsible themselves for the timing of its appearance. Interestingly, from studies of patients with monogenic causes of obesity who develop obesity and hyperphagia earlier than in PWS, it is apparent that the brain pathways mediating the action of leptin, including the central melanocortin system, are functional before the usual age of development of hyperphagia in PWS (at 4 --5 years). 53 Indeed, ghrelin, PP and insulin are thought to affect eating behaviour through these leptin-melanocortin-PVN pathways. 19, 20 Furthermore, although deficiency of anorexigenic oxytocin neurons in the PVN may contribute to hyperphagia in PWS, 16 hyperphagia in patients with chromosomal deletions or translocations involving the SIM1 gene (which in animals impairs development of PVN neurons 54 ) develops earlier than in PWS. 55 Therefore, it might be hypothesised that there is at least delayed, if not also abnormal, development of effector feeding pathways in PWS that may interact with hormonal abnormalities.
Pancreatic polypeptide Previous studies have found that, compared with non-obese and obese controls, fasting levels of PP are either normal 22, 23, 45 or decreased, 10, 21, 35 and post-prandial levels decreased, 10,21 --23,35,45 in both children over the age of 5 --7 years and adults with PWS. Although eating behaviour was rarely described in the non-adult studies, most of the children did have marked obesity. The current study extends these findings to reveal that fasting PP levels are also lower than in controls between 1 --5 years, well before the development of hyperphagia. PP is an anorexigenic gut hormone that acts through Y4 receptors in hypothalamic feeding nuclei. 19 Furthermore, infusion of PP has a small effect to reduce food intake in patients with PWS, 56 and is also anorexigenic in non-obese non-PWS subjects. 19 It is therefore possible that there is a primary defect in pancreatic function in PWS. Although this could be present from birth, the absence of control samples from children under 12 months in our study does not allow such an inference. Interestingly, PWS genes are expressed in the mouse pancreas, and a mouse deletion model of PWS displays low embryonic and neonatal insulin and glucagon levels, impaired b-cell insulin secretion, reduced a-and b-cell mass with increased apoptosis and upregulation of mRNA for pancreatic insulin, glucagon, PP and other secretory factors. 57 However, plasma PP levels have not been reported in PWS mouse models.
However, there may be species differences. While fasting or post-prandial insulin levels have sometimes been reported as low in human PWS children, 44, 58 this has not been found in the current study and others. 28, 39, 41, 45, 48 In addition low fasting and postprandial insulin levels in PWS children and adults may be related more to preserved insulin sensitivity than reduced insulin secretion, as supported by reduced hypertriglyceridaemia and altered levels of related adipocytokines, such as increased plasma adiponectin in PWS. 23, 24, 29, 30, 34, 38, 45, 48 Similar discrepancies have been seen for glucagon with fasting levels reported as low in one study of PWS children (410 years) and adults, 25 but normal fasting and post-prandial glucagon levels in another adult study. 35 
Ghrelin
Previous studies have consistently shown that fasting plasma ghrelin levels are raised in older children (after the usual age of development of hyperphagia) and adults with PWS relative to their obesity, up to 3 --4 fold higher in PWS than controls adjusting for BMI or body composition. 26,27,32,34,36 --38,40,43 --48 Levels of ghrelin do fall after food intake in children and adults with PWS but remain elevated compared with the controls relative to their obesity. 37, 38, 40, 43, 44 In our current study, we were unable to demonstrate any elevation of plasma ghrelin levels in PWS children under 5 years, unadjusted or when correcting for age, BMI, fasting insulin or insulin resistance. This finding is in agreement with previous studies of PWS children aged under 3 or 5 years, 39, 42, 46 although it should be noted that one of these studies did not find hyperghrelinaemia in PWS children over 3 years and adults either. 42 The findings from these studies suggest that hyperghrelinaemia does not precede or coincide with the development of hyperphagia in PWS children. However, this conclusion is contradicted by the largest study that found elevated fasting plasma ghrelin levels in PWS children under 3 years. 47 It is possible that these discrepancies are related to the smaller size of the negative studies, including our own. 39, 42, 46 Furthermore, hyperghrelinaemia in older children and PWS adults may be partially, though not solely, explained by preserved insulin sensitivity and relative hypoinsulinaemia, as ghrelin levels are negatively correlated with insulin. 29, 34, 38, 40, 46, 47 Ghrelin levels also rise with starvation and weight loss. 18, 20 Thus, differences between studies might also depend on differences in the dynamic nutritional state, body composition and insulin status. In those studies of PWS young children, where hyperghrelinaemia was not seen, insulin levels were either normal or raised (current study and Erdie-Lalena et al.
39
; Haqq et al. 46 ), while in the study in which hyperghrelinaemia was seen, there was a suggestion that insulin levels were lower in the PWS young children (although insulin levels were not available in all subjects). 47 Indeed, body composition parameters varied widely between these studies, with range of weight for length Z scores À0.69 to þ 1.67, 46 BMI SDS À1.86 to þ 5.79 (current study) and BMI Z score À4.0 to þ 2.0. 47 Furthermore, these studies have only measured total ghrelin and did not distinguish between desacyl and active acyl ghrelin, although elevations in the active form in PWS children over 6 years 40 and adults 38 are reported.
PYY
Fasting PYY levels in PWS did decline with age (more steeply than in controls) and eating code in our study. However, we found overall normal fasting PYY levels in PWS children under 5 years compared with the controls, in agreement with other studies in children over 4 or 11 years 41, 44 and adults. 38, 43, 59 One study has reported elevated fasting PYY levels in PWS children over 7 years. 45 Post-prandial PYY levels have generally been found to be normal in PWS children and adults, 38, 41, 44 though one study found decreased post-prandial levels. 43 Similarly fasting plasma levels of the anorexigenic gut hormone GLP-1 that is cosecreted from intestinal L-cells with PYY appear normal in PWS children and adults, 10, 34, 38, 48 and post-prandial GLP-1 levels are normal in PWS adults PWS. 10, 38 Fasting and post-prandial plasma levels of CCK 11, 23, 25, 41 and GIP, 21, 38, 45 other gut hormones involved in appetite regulation and glucose homeostasis, also appear normal in PWS children (over 7 --11 years) or adults. It therefore seems unlikely that deficiency of anorexigenic hormone PYY (or these other gut hormones) has a pathogenic role in hyperphagia in PWS.
Leptin
This study found fasting leptin levels to be higher in PWS children under 5 years than controls irrespective of age, BMI or insulin resistance, in agreement with a previous study of children under 3 years, 46 suggesting excess fat mass for age and size from an early age. This supports anthropometric studies that babies, infants and young children with PWS have reduced muscle mass, and increased fat mass, 60 and that BMI underestimates adiposity in PWS. 31 In PWS adults, leptin levels are normal when correcting appropriately for body composition. 31 Study limitations An obvious limitation of our study is the small number of control subjects, which may have led to a type II error. Caution should therefore be made in assessment of the differences in hormone levels between groups and in particularly in the lack of any difference in ghrelin and PYY levels. The use of controls that were having routine fasting blood samples collected before the surgery was stipulated by the ethics committee and proved a major barrier to recruitment. However, the finding of low PP levels in PWS compared with the controls was still found despite this low number. Future studies using larger numbers of controls, where ethically possible, will be needed to confirm our findings.
The colinearity of age with eating code in PWS subjects may also have made it difficult to tease out more subtle-associated changes in appetitive hormones over the natural history of hyperphagia development. Larger cohorts of both PWS and control subjects will enable correlation of hormone SDS scores with eating code in PWS. Our study was also cross-sectional rather than longitudinal, and so it will be important to gather prospective data from cohorts of PWS neonates and infants. Furthermore, this study only examined fasting hormone levels, and not post-prandial levels, which in the case of ghrelin, insulin, PP and PYY may miss abnormalities, as levels change after food ingestion.
The youngest age of the PWS subject in this study was 7 months. In future studies it will be important to include younger neonates and infants with PWS, especially those who have poor feeding and failure-to-thrive, as this may be associated with causative or secondary changes in appetite hormones.
Summary
This cross-sectional study of PWS children under the age of 5 years did not find evidence for changes in the fasting plasma levels of ghrelin, PP, PYY, leptin or insulin to be related to the development of the PWS eating phenotype across ages. Compared with controls, PWS infants and young children did, however, have evidence of raised leptin levels and reduced fasting PP levels even from 1 year, several years before the onset of hyperphagia, while fasting ghrelin, PYY and insulin levels were normal. Therefore, it seems likely that changes in the central pathways controlling appetite regulation and food reward are responsible for the evolution of hyperphagia in PWS. These initial observations warrant further investigation in larger prospective longitudinal cohorts of neonates, infants and young children with PWS and controls, examining the relationship with body composition and eating behaviour.
